文献速递免疫规划传染病防控与疫情报告

英格兰50岁以上成人二价BA.1 mRNA加强针有效性观察性匹配队列研究

Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY.
PubMed 文献 · Vaccine · 2026-02-18

该研究利用OpenSAFELY-TPP平台数据,采用模拟目标试验的匹配队列设计,评估50岁以上成人接种二价原始/奥密克戎BA.1 mRNA加强针(Moderna或Pfizer-BioNTech)对COVID-19住院和死亡的有效性。结果显示,与未加强相比,接种后350天内COVID-19住院和死亡风险显著降低,但保护随时间减弱,两品牌疫苗对COVID-19结局相似。

要点

  • 二价BA.1 mRNA加强针可降低50岁以上成人COVID-19住院和死亡风险。
  • 加强针保护随时间减弱,接种后70天内效果最强。
  • Moderna和Pfizer-BioNTech疫苗对COVID-19住院和死亡风险相似。

核心结论

  • 接种二价原始/奥密克戎BA.1 mRNA加强针后COVID-19相关住院和死亡风险显著低于未加强者。
  • 疫苗保护随时间减弱,接种后70天内效果最强。
  • 两品牌疫苗对COVID-19住院和死亡风险相似,但Moderna组非COVID-19死亡风险略高。

研究设计与样本

  • 匹配队列研究,模拟目标试验。
  • 数据来自OpenSAFELY-TPP平台链接的初级保健、医院和COVID-19监测记录。
  • 比较加强接种与未加强:3,464,877名符合2022年秋季加强接种条件的50岁以上成人。
  • 疫苗间比较:531,129对加强接种者。

主要发现

  • 接种后350天COVID-19住院风险为3.78/1000(95%CI 3.65-3.91),未接种为6.81/1000(6.65-6.98)。
  • 接种后350天COVID-19死亡风险为0.29/1000(0.26-0.33),未接种为0.61/1000(0.56-0.66)。
  • 调整后风险比:COVID-19住院0.51(0.50-0.53),COVID-19死亡0.45(0.40-0.51),非COVID-19死亡0.56(0.55-0.58),骨折0.89(0.87-0.91)。
  • 两品牌疫苗对COVID-19住院、死亡和骨折的350天风险相似,但Moderna组非COVID-19死亡风险差异为0.88/1000(0.35-1.40)。

临床怎么用

  • 支持在50岁以上成人中推广二价BA.1 mRNA加强针以降低COVID-19住院和死亡风险。
  • 加强针保护随时间减弱,需关注后续加强策略的时机。
  • 疫苗品牌选择对COVID-19结局影响相似,但需注意非COVID-19死亡风险的潜在差异。

局限性

  • 观察性设计可能存在未测量混杂,骨折阴性对照结果提示存在残余混杂。
  • 结果可能受限于OpenSAFELY-TPP平台覆盖人群的特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Estimate the effectiveness and comparative effectiveness of booster vaccination with bivalent original/omicron BA.1 mRNA-1273 (Moderna) and original/omicron BA.1 BNT162b2 (Pfizer-BioNTech) against COVID-19 hospitalisation and death in adults aged ≥50 years. DESIGN: Matched cohort studies emulating target trials. SETTING: With approval of NHS England, we analysed linked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform. PARTICIPANTS: For comparison of boosting with no boosting, 3,464,877 adults eligible for booster vaccination during the autumn 2022 UK COVID-19 vaccine rollout, registered with a general practice using the TPP SystmOne clinical information system in England. For the between-vaccine comparison 531,129 boosted pairs. INTERVENTIONS: Vaccination with bivalent BA.1 mRNA-1273 or BNT162b2. MAIN OUTCOME MEASURES: COVID-19-related hospital admission or death, non-COVID-19 death, fracture (negative control outcome). RESULTS: In approximately 2.5-million person-years follow up there were 14,436 COVID-19-related hospital admissions, 1152 COVID-19-related deaths, 32,184 non-COVID-19 deaths, and 52,758 fractures. The 350-day risks/1000 of COVID-19 hospitalisation and COVID-19 death were 3.78 (95% CI 3.65-3.91) and 0.29 (0.26, 0.33) respectively after boosting and 6.81 (6.65-6.98) and 0.61 (0.56, 0.66) without boosting. Over 350 days' follow-up, adjusted hazard ratios were: COVID-19 hospitalisation 0.51 (95% CI 0.50, 0.53); COVID-19 death 0.45 (0.40, 0.51); non-COVID-19 death 0.56 (0.55, 0.58) and fracture 0.89 (0.87, 0.91). Booster effectiveness waned over time, with greatest effectiveness in the first 70 days after vaccination. The 350-day risks of COVID-19 hospitalisation, COVID-19 death and fracture were similar for the two vaccine brands but higher in the bivalent mRNA-1273 group for non-COVID-19 death (risk difference per 1000 0.88 [0.35, 1.40]). CONCLUSIONS: Rates of COVID-19-related hospitalisation and death were substantially lower after bivalent original/omicron BA.1 mRNA booster vaccine than in people who remained unboosted. Apparent protection against fracture suggests some unmeasured confounding. Outcomes appeared similar for the Moderna and Pfizer-BioNTech vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Madley-Dowd P, Horne EMF, Hulme WJ, et al. Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY. Vaccine. 2026. PMID: 41708420. doi:10.1016/j.vaccine.2026.128276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。